SCHEMBL20239205

SCHEMBL20239205

CS(=O)(=O)Nc1ccc(Oc2cc(C#N)nc(N3CCOCC3)n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.49
CTSS P25774 3/20 0.48
CTSK P43235 3/20 0.48
CTSL P07711 2/20 0.48
CTSB P07858 2/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
TSHR P16473 1/20 0.48
HTT P42858 1/20 0.48
HSD17B10 Q99714 1/20 0.48
ALDH1A1 P00352 2/20 0.47
CYP2D6 P10635 1/20 0.47
ATM Q13315 1/20 0.47
MTOR P42345 2/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239202 0.80 LMNA (0.54) LMNASMN1; SMN2CTSSCTSKCTSL
SCHEMBL20239364 0.76 DGAT2 (0.62) LMNASMN1; SMN2KMT2AMEN1CYP1A2
SCHEMBL20239281 0.70 DGAT2 (0.61) LMNASMN1; SMN2KMT2AMEN1CYP1A2
SCHEMBL10847885 0.69 KMT2A (0.62) LMNASMN1; SMN2KMT2AMEN1CYP1A2
SCHEMBL13848207 0.69 PIK3CA (0.55) CYP1A2CYP2C9CYP2C19TSHRHTT
SCHEMBL20239278 0.69 PGR (0.47) LMNASMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL3990242 0.67 PIK3CA (0.60) MTORJAK2JAK3
SCHEMBL31086601 0.67 LMNA (0.55) LMNASMN1; SMN2CTSSCTSKCTSL
SCHEMBL2471989 0.67 CYP1A2 (0.67) SMN1; SMN2CTSSCTSKCTSLCTSB
SCHEMBL3992080 0.67 ALDH1A1 (0.65) LMNASMN1; SMN2KMT2AMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT LMNA 2022/4885SMN1; SMN2 4828/4885CTSS 2516/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT LMNA 1722/4885SMN1; SMN2 4835/4885CTSS 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.